Pateron D, Babany G, Hadengue A, Delafosse B, Degott C, Sylvain C, Larrey D, Benhamou J P
Service d'Hépatologie, (INSERM U 24), Hôpital Beaujon, Clichy.
Gastroenterol Clin Biol. 1990;14(5):504-6.
We report two cases of fulminant hepatitis which might be due to toloxatone, a new type-A monoamine oxidase inhibitor. Hepatitis occurred 20 days after the beginning of toloxatone administration in the first case and 138 days after the reintroduction of treatment in the second case. Clinical features included vomiting and jaundice, followed by asterixis and coma. Histologically, hepatic cell necrosis was predominant in the centrilobular area in the first case, and affected the entire lobule in the second case. Both patients died despite emergency liver transplantation.
我们报告了两例暴发性肝炎病例,可能是由新型A型单胺氧化酶抑制剂托洛沙酮所致。第一例在开始服用托洛沙酮20天后出现肝炎,第二例在重新开始治疗138天后出现肝炎。临床特征包括呕吐和黄疸,随后出现扑翼样震颤和昏迷。组织学上,第一例中央小叶区以肝细胞坏死为主,第二例累及整个小叶。尽管进行了紧急肝移植,两名患者均死亡。